The German startup Kumovis, which developed the R1 3D printer specifically for medical applications and a portfolio of medical polymers, has opened a US subsidiary. Kumovis Inc. is laying the foundation for business relationships with partner companies in North America, where installations of its signature 3D printers are already underway, the company said. The location of the subsidiary was not mentioned.
The Munich spin-out of the Technical University of Munich was founded in 2017 and presented the 3D printers of the R1 series in summer 2019. Based on Fused Deposition Modeling, the R1 aims to manufacture medical technology companies and hospitals in a resource-efficient way. Kumovis claims that its process is more cost and time efficient than milling or injection molding to produce patient-specific medical devices and small batch products.
Last year, Kumovis expanded its range of medical grade polymers, which now includes carbon fiber reinforced PEEK (PEEK CF); PPSU mixed with barium sulfate (PPSU + BaSO4) for improved radiopacity; and PEI and absorbable polymers PLLA, PLGA, PCL and PDO.
The medical 3D printing market is still relatively small – it is projected to reach $ 5.1 billion by 2026 – but according to a recent report from ResearchAndMarkets, the average annual growth rate is projected to be a robust 16 between 2021 and 2026 .3% lie.
Kumovis names cranial implants, spinal fusion devices and medical instruments as applications where 3D printing offers new possibilities. It is currently partnering with Drexel University in Philadelphia, which is using a predecessor machine to the R1 to advance the use of 3D printing in U.S. healthcare beyond anatomical models and surgical instruments, the company said.
“With its potential beyond craniomaxillofacial applications and its openness to innovative 3D printing solutions for the healthcare sector, the future is particularly promising for US hospitals and medical device manufacturers,” said Kumovis in the press release announcing its expansion into the US market.